Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Subscribe To Our Newsletter & Stay Updated
